OverviewSuggest Edit

The Nurix scientific team has established an innovative drug discovery platform based on recent advances in understanding of the ubiquitin proteasome system (UPS). The UPS is a regulatory network that controls protein homeostasis, the stabilization and degradation of cellular proteins. This process is vital to the healthy life of a cell and provides opportunities to discover new drugs in multiple disease areas. Nurix’s Protein Regulation Platform enables the discovery of selective inhibitors or activators of the UPS, enabling the development of new class of drugs. In September 2015, Nurix entered into an exclusive collaboration with Celgene for the discovery and development of next-generation therapies targeting protein homeostasis in oncology, immunology and inflammation, including the rapidly evolving field of immuno-oncology. Nurix was founded by internationally-recognized experts in the ubiquitin proteasome field and is funded by leading life science investors Third Rock Ventures and The Column Group. The company is headquartered in San Francisco, California.
TypePrivate
HQSan Francisco, US
Websitenurix-inc.com

Latest Updates

Employees (est.) (Oct 2019)93(+4%)

Key People/Management at Nurix

Tim Kutzkey

Tim Kutzkey

Chairman
Arthur T. Sands

Arthur T. Sands

Chief Executive Officer and Board Director
David Lacey

David Lacey

Board Director
Jeff Tong

Jeff Tong

Board Director
Robert Tjian

Robert Tjian

Board Director
Show more

Nurix Office Locations

Nurix has an office in San Francisco
San Francisco, US (HQ)
1700 Owens St #205, San Francisco
Show all (1)

Nurix Financials and Metrics

Summary Metrics

Nurix total Funding

$28.2 m

Nurix latest funding size

$25.10 m

Time since last funding

5 years ago

Nurix investors

Nurix's latest funding round in May 2014 was reported to be $25.1 m. In total, Nurix has raised $28.2 m
Show all financial metrics

Nurix Online and Social Media Presence

Embed Graph

Nurix News and Updates

Gilead strikes deal with Nurix Therapeutics to tackle disease-causing proteins

Gilead Sciences Inc. is partnering with Nurix Therapeutics, a biotech working on drugs to destroy disease-causing proteins, the companies announced Wednesday. Under the terms of the multi-year deal, Gilead will have the option to license certain drug candidates from Nurix, and Nurix will have the …

Nurix Blogs

Nurix Therapeutics to Present at the Targeted Protein Degradation Summit 2019

SAN FRANCISCO, October 15, 2019 – Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, today announced that Arthur Sands, M.D., Ph.D., chief executive officer, and Gwenn Hansen, Ph.D., senior vice president, research, will present at the Targeted Protein De…

Director of Regulatory Affairs

Position Summary: The Head of Regulatory Affairs at Nurix will have primary responsibility for the oversight and management of Regulatory matters related to Nurix’s commercial and development product pipeline globally in coordination with key internal stakeholders. In conjunction with that, the Dire…

Senior Research Scientist / Scientist, Translational Medicine

Position The successful candidate will be responsible for the design and implementation of biomarker assays to support Nurix’s clinical development programs targeting protein fate for cancer targeted therapy and immunotherapy.  Collaborating with the Discovery and Development organizations, the tran…

Nurix Therapeutics Announces Key Additions to its Board of Directors

SAN FRANCISCO, October 8, 2019 – Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, today announced Lori A. Kunkel, MD and Julia Gregory have joined its board of directors. In addition, David Lacey, MD, a current board director, h…

Senior Research Scientist – Protein Sciences

Position We are seeking a highly skilled and motivated Scientist with expertise in Protein Sciences to join Nurix’s Protein Sciences group. Nurix is devoted to unlocking the therapeutic potential of the ubiquitin proteasome system (UPS) in the areas of oncology and immuno-oncology, by utilizing the …

Scientist I – Protein Sciences

Position We are seeking a highly skilled and motivated Scientist with expertise in Protein Sciences to join Nurix’s Protein Sciences group. Nurix is devoted to unlocking the therapeutic potential of the ubiquitin proteasome system (UPS) in the areas of oncology and immuno-oncology, by utilizing the …
Show more

Nurix Frequently Asked Questions

  • Who are Nurix key executives?

    Nurix's key executives are Tim Kutzkey, Arthur T. Sands and David Lacey.

  • How many employees does Nurix have?

    Nurix has 93 employees.

  • Who are Nurix competitors?

    Competitors of Nurix include Innate Pharma, DBV Technologies and Cord Blood America.

  • Where is Nurix headquarters?

    Nurix headquarters is located at 1700 Owens St #205, San Francisco, San Francisco.

  • Where are Nurix offices?

    Nurix has an office in San Francisco.

  • How many offices does Nurix have?

    Nurix has 1 office.